Drug General Information
Drug ID
D00RRU
Former ID
DNCL001928
Drug Name
BIIB037
Indication Alzheimer disease [ICD9: 331; ICD10:G30] Phase 3 [525246]
Company
Biogen Idec
Target and Pathway
Target(s) Amyloid beta A4 protein Target Info Modulator [544313]
KEGG Pathway Notch signaling pathway
Alzheimer's disease
Reactome Nuclear signaling by ERBB4
Degradation of the extracellular matrix
Regulated proteolysis of p75NTR
NRIF signals cell death from the nucleus
Activated NOTCH1 Transmits Signal to the Nucleus
Constitutive Signaling by NOTCH1 PEST Domain Mutants
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
EPH-ephrin mediated repulsion of cells
WikiPathways Notch Signaling Pathway
Signaling by ERBB4
Signaling by NOTCH3
Signaling by NOTCH4
Signaling by NOTCH1
Signaling by NOTCH2
Notch Signaling Pathway
Alzheimers Disease
Signalling by NGF
References
Ref 525246ClinicalTrials.gov (NCT02484547) 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease.
Ref 544313Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets?. Immun Ageing. 2013; 10: 18.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.